Lemtrada (alemtuzumab) / Sanofi 
Welcome,         Profile    Billing    Logout  
 8 Diseases   17 Trials   17 Trials   2602 News 


«12345678910111213...2425»
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
    Journal:  Alemtuzumab-induced Graves' disease (Pubmed Central) -  Jul 18, 2023   
    The patient was referred to a radiologist at the Department of Radionuclide Therapy of Endocrinology Research Centre for radioiodine therapy (RAIT) due to relapse of thyrotoxicosis after anti-thyroid drug therapy for GD. The goal of treatment was achieved in 2 months, thyroid hormone therapy was initiated, against the background of this, there was compensation of thyroid function.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Observational data, Journal:  Long-lasting neutralizing antibodies and T cell response after the third dose of mRNA anti-SARS-CoV-2 vaccine in multiple sclerosis. (Pubmed Central) -  Jul 10, 2023   
    The frequency of Spike-specific IFN?-producing CD4+ and CD8+ T cells was measured by stimulating Peripheral Blood Mononuclear Cells (PBMCs) with a pool of peptides covering the complete protein coding sequence of the SARS-CoV-2 S. Blood samples from 70 pwMS (11 untreated pwMS, 11 under dimethyl fumarate, 9 under interferon-?, 6 under alemtuzumab, 8 under cladribine, 12 under fingolimod and 13 under ocrelizumab) and 24 healthy donors were collected before and up to six months after three vaccine doses...Altogether, our observations highlight the vaccine response data to current protocols in pwMS and underline the necessity to carefully follow-up anti-CD20- treated patients for higher risk of breakthrough infections. Our study may provide useful information to refine future vaccination strategies in pwMS.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
    Journal:  Alemtuzumab treatment in real clinical practice: Experience in a multicenter cohort. (Pubmed Central) -  Jun 19, 2023   
    Of the newer therapies, only ublituximab ranked among the three most efficacious treatments (for ARR). Alemtuzumab has demonstrated in real clinical practice high effectiveness in controlling multiple sclerosis activity, and no unexpected adverse events were observed.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Review, Journal:  Disease-modifying therapy for multiple sclerosis: Implications for gut microbiota. (Pubmed Central) -  Jun 5, 2023   
    However, the association between DMTs exposure and microbial changes was mostly indirect, and the results of the different studies needed to be more consistent. The mitigation of methodological bias is necessary for future studies to allow the identification of a "microbial signature" related to MS pathophysiology, the role of DMTs, and possible prognostic implications.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Use of newer disease modifying therapies in paediatric multiple sclerosis in Slovenia (Foyer 3B, 3rd Floor) -  May 29, 2023 - Abstract #EPNS2023EPNS_577;    
    They have comparable side effects to injectable DMTs, while other studies suggest that they lead to better disease activity control. Further research is needed to develop optimal guidelines for treatment of paediatric MS.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Lemtrada (alemtuzumab) / Sanofi
    Review, Journal:  Monoclonal Antibodies in Pregnancy and Breastfeeding in Patients with Multiple Sclerosis: A Review and an Updated Clinical Guide. (Pubmed Central) -  May 27, 2023   
    As a result, monoclonal antibodies, including natalizumab, alemtuzumab, ocrelizumab, ofatumumab, and ublituximab, are frequently used for the treatment of MS in women of childbearing age...We aim to provide an updated overview of the mechanisms of action, risks of exposure and treatment withdrawal, and pre-conception counseling and management during pregnancy and post-partum of monoclonal antibodies in women with MS. Discussing treatment options and family planning with women of childbearing age is essential before commencing a DMT in order to make the most suitable choice for each individual patient.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Journal:  The Impact of SARS-CoV-2 Infection in Multiple Sclerosis Patients taking Disease- Modifying Therapies. (Pubmed Central) -  May 26, 2023   
    B-cell depleting agents (ocrelizumab and rituximab) were given to 19 patients, another 19 were on immune cell Traffickers (fingolimod and natalizumab) and 13 were on other DMT treatments (alemtuzumab, cladribine, interferon-beta, dimethyl fumarate, and teriflunomide)...None experiences MS relapses during infection. Two patients on rituximab had a moderate course of the illness, which required hospitalization for oxygen support, but did not need mechanical ventilation and the rest remained asymptomatic.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
    Grave's disease secondary to Alemtuzumabuse (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_2502;    
    We were just initially able to treat her with prednisone, beta blocker and cholestyramine with close biochemical monitoring as an outpatient...At this time, she remains to be on methimazole as an outpatient...To our knowledge, there is no published case with reported ALZ-induced Grave's disease with this length of interval since infusion. Our case highlights not only the importance of pretreatment screening but continued vigilance and close thyroid function monitoring in patients treated with ALZ even several years after therapy.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Journal, Discordant:  Alemtuzumab treatment exemplifies discordant immune effects of blood and cerebrospinal fluid in multiple sclerosis. (Pubmed Central) -  May 8, 2023   
    Our case highlights not only the importance of pretreatment screening but continued vigilance and close thyroid function monitoring in patients treated with ALZ even several years after therapy. The CSF and blood compartments are thus partially uncoupled, emphasizing that the CNS is only partially accessible even for treatments profoundly affecting the blood.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Journal:  Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis. (Pubmed Central) -  Mar 15, 2023   
    EIT presents higher efficacy in preventing disability progression, a similar safety profile, and can be cost-effective within a 5-year timeline. The use of AHSCT in people with active SPMS is associated with a slowing of disability progression and a higher likelihood of disability improvement compared with standard immunotherapy.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    A Real-life study of Alemtuzumab in patients with Multiple Sclerosis: Kuwait (Both in-person and online) -  Mar 12, 2023 - Abstract #AAN2023AAN_4200;    
    Conclusions The effectiveness and safety profile of Alemtuzumab in this cohort were consistent with data of clinical trials. Early initiation of Alemtuzumab is associated with favorable outcome.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Real-world effectiveness of switching treatment after initial platform injectable disease-modifying therapies in pediatric multiple sclerosis in the US (Both in-person and online) -  Mar 12, 2023 - Abstract #AAN2023AAN_4196;    
    Design/Methods This is a cohort study of pediatric MS/CIS at 12 clinics in the US Network of Pediatric MS Centers, who received initial therapy with platform injectable (interferon-?, glatiramer acetate) and switched to other injectable, oral (dimethyl fumarate, fingolimod, teriflunomide) or infusion (natalizumab, rituximab, ocrelizumab, alemtuzumab) DMT...Conclusions Switching from platform injectable to oral or infusion vs another injectable DMT led to better disease activity control of pediatric MS. Long-term safety data for oral and infusion DMTs are required.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
    Delayed Onset Cryptogenic Organizing Pneumonia in Alemtuzumab Treatment Patient (Both in-person and online) -  Mar 12, 2023 - Abstract #AAN2023AAN_4192;    
    She was initially treated with interferon beta-1a and glatiramer acetate injections, but discontinued due to drug intolerance...Due to concern for worsening lower extremity edema and obesity, she was eventually transitioned from prednisone to mycophenolate mofetil...Conclusions We present a rare, non-infectious steroid-responsive lung disorder following alemtuzumab administration. While autoimmunity is common following alemtuzumab treatment, delayed onset cryptogenic organizing pneumonia has not been reported with its use in the literature.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
    New Mitigation Protocol for Alemtuzumab Infusion Related Reactions in a Chilean Cohort (Both in-person and online) -  Mar 12, 2023 - Abstract #AAN2023AAN_2827;    
    Conclusions The NMP decreases the occurrence of IRRs during the first and second cycle of alemtuzumab compared to the SMP. Larger cohorts are needed to reduce biases and to analyze the impact of the NMP during third or fourth cycle or the impact in other infusion related reactions that are less frequent.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Journal:  Thyroid autoimmunity following alemtuzumab treatment in multiple sclerosis patients: a prospective study. (Pubmed Central) -  Jan 16, 2023   
    Our analysis showed earlier onset of ALZ-induced AITD in comparison to most other ALZ cohorts; overall, these patients required complex therapeutic approaches of the AITD. We observed a higher rate of fluctuating GD, with earlier onset and lower remission rate than previously reported, which in the majority of patients required prolonged "block and replace" therapy in the minimum dose of each therapeutic agent or more definitive interventions.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Pregnancy Outcomes in Multiple Sclerosis patients with or without exposure to Disease Modifying Therapies during pregnancy (Both in-person and online) -  Jan 7, 2023 - Abstract #AAN2023AAN_427;    
    Design/Methods In this prospective, observational cohort from the German MS and Pregnancy Registry, we analyzed spontaneous abortions (SA), mean birth weight, preterm births, still births and major congenital abnormalities (MCA) in women with/without DMT pregnancy exposure, stratified into different DMT exposure groups (inferferon-b, glatiramer acetate, dimethyl fumarate, fingolimod, natalizumab, ocrelizumab/rituximab, others)...The findings that corticosteroid and fingolimod exposure and also DMT continuation (mainly NTZ) were associated with a reduced birth weight warrant further comparisons not only with unexposed pregnancies. Limitations include the small sample size of
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Journal:  Circulating CCR6ILC proportions are lower in multiple sclerosis patients. (Pubmed Central) -  Dec 30, 2022   
    MS patients prior to alemtuzumab further displayed proportional shifts from ILC1 to ILC2, with MS-associated decreases in CCR6 helper ILC proportions. CD56 NK cells during relapse indicate an immediate response to disease reactivation, while CCR6-related shifts among helper ILC suggest altered ILC migration to the CNS during MS.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Journal:  Follow up examination of multiple sclerosis patients treated with alemtuzumab in Multiple Sclerosis Centre, Szeged (Pubmed Central) -  Dec 22, 2022   
    Infection related to the therapy was observed in 28.6%, while autoimmune thyreoiditis was diagnosed in 18.3% of the patients. The tight follow-up of the treated patients and the precise documentation of the register enable the comparison of results yielded by placebo controlled clinical studies with daily practice, as well as to gain information on the benefits of induction therapy as a paradigm shift in treating MS patients.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
    Disseminated Histoplasmosis after Alemtuzumab () -  Dec 16, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_1088;    
    Conclusion To our knowledge, this is the fourth report of histoplasmosis after alemtuzumab, and the first in a patient who received it for T-PLL (Figure 3). Disseminated histoplasmosis can be a potential infectious complication of the profound immunosuppression resulting from alemtuzumab and the underlying diseases it is used to treat, and should be considered in patients with unexplained cytopenias or other systemic symptoms, particularly in endemic areas.